⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283408 | 1.00 | — | — | |
| SCHEMBL515078 | 1.00 | — | — | |
| SCHEMBL13653186 | 0.78 | — | — | |
| SCHEMBL642779 | 0.76 | — | — | |
| SCHEMBL642780 | 0.76 | — | — | |
| SCHEMBL19262024 | 0.73 | — | — | |
| SCHEMBL470592 | 0.73 | — | — | |
| SCHEMBL336281 | 0.73 | ALDH1A1 (0.46) | — | |
| SCHEMBL873627 | 0.73 | — | — | |
| SCHEMBL470639 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2023210818-A1 | COMPOSITION INCLUDING FLUORORUBBER | ダイキン工業株式会社 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023195485-A1 | COMPOSITION AND CROSSLINKED PRODUCT | ダイキン工業株式会社 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023189547-A1 | COMPOSITION, CROSSLINKED PRODUCT, AND SEALING MATERIAL | ダイキン工業株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-116102449-A | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-108349901-B | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-7632852-B2 | (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157751-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1853595-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087480-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | WO | disclosed |